Caspase-Cleaved Glial Fibrillary Acidic Protein Within Cerebellar White Matter of the Alzheimer\u27s Disease Brain by Rohn, Troy T. et al.
Boise State University
ScholarWorks
Biology Faculty Publications and Presentations Department of Biological Sciences
1-1-2013
Caspase-Cleaved Glial Fibrillary Acidic Protein







Institute for Memory Impairments and Neurological Disorders
This document was originally published in International Journal of Clinical and Experimental Pathology . This work is provided under a Creative
Commons Attribution-NonCommercial 3.0 license. Details regarding the use of this work can be found at: http://creativecommons.org/licenses/by-
nc/3.0/. http://www.ijcep.com/
Int J Clin Exp Pathol 2013;6(1):41-48
www.ijcep.com /ISSN:1936-2625/IJCEP1209010
Original Article
Caspase-cleaved glial fibrillary acidic protein within  
cerebellar white matter of the Alzheimer’s disease brain
Troy T Rohn1, Lindsey W Catlin1, Wayne W Poon2
1Department of Biology, Boise State University, Boise, ID 83725, USA; 2Institute for Memory Impairments and Neu-
rological Disorders, UC Irvine, Irvine CA 92697, USA
Received September 17, 2012; Accepted October 25, 2012; Epub November 20, 2012; Published January 1, 
2013
Abstract: Although the cerebellum is generally thought of as an area spared of Alzheimer’s disease (AD) pathology, 
recent evidence suggests that balance and mobility dysfunction may be magnified in affected individuals. In the 
present study, we sought to determine the degree of pathological changes within the cerebellum utilizing an anti-
body that specifically detects caspase-cleaved GFAP within degenerating astrocytes. Compared to control subjects, 
application of this antibody, termed the GFAP caspase-cleavage product (GFAPccp) antibody, revealed widespread 
labeling in cerebellar white matter with little staining observed in grey matter. Staining was observed within dam-
aged astrocytes, was often localized near blood vessels and co-localized with other markers of apoptosis including 
TUNEL and caspase-cleaved tau. Of interest was the association of beta-amyloid deposition in white matter together 
with GFAPccp in cerebellar AD sections. In contrast, utilizing the tangle marker, PHF-1, neuritic pathology was com-
pletely absent in AD cerebellar sections. It is suggested that the observed pathological changes found in the white 
matter of the cerebellum may contribute to the declined motor performance in AD.
Keywords: GFAP, caspase, cerebellum, Alzheimer’s disease, neurofibrillary tangles, TUNEL, beta amyloid, immuno-
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Introduction
The cerebellum is a subcortical brain structure 
that is essential for learning and controlling 
movement [1]. The cerebellum does not initiate 
movement, but it contributes to the proper tim-
ing, coordination, and fine-tuning precision of 
movement [2]. Consequently, lesions in the cer-
ebellum may lead to postural instability, loss of 
balance and of normal gait [3]. While Alzheimer’s 
disease (AD) is characterized by the extent of 
plaques and tangles predominantly within the 
hippocampus and cortex, the cerebellum is 
thought to be largely spared of pathology and is 
often used as an area of comparison (for exam-
ple see, [4, 5]). In this regard, studies in AD 
have documented the relative lack of neuro-
pathological changes in the cerebellum includ-
ing the integrity of granule cell number and 
density [6]. However, several studies have indi-
cated that despite the absence of tau patholo-
gy [7, 8], it is not uncommon to find diffuse amy-
loid deposits both in the granular cell layer as 
well as in white matter of the cerebellum of AD 
subjects [9-11]. 
In spite of the relative lack of pathology associ-
ated with the cerebellum, several studies have 
documented mobility dysfunction, loss of bal-
ance, and an increase risk for falls in Alzheimer’s 
patients as compared to nondemented controls 
[12-16]. The motor impairments, including gait 
and balance dysfunctions in AD might suggest 
that pathological changes are evident in this 
structure that may occur independently of neu-
ritic changes due to the lack of neuropathology 
found in the cerebellum. To examine this possi-
bility, we tested for the presence of white mat-
ter changes utilizing an antibody (GFAPccp) that 
specifically detects caspase-cleaved GFAP 
within degenerating astrocytes of the AD brain 
[17-19]. Using this antibody, we now document 
the labeling of damaged astrocytes along blood 
vessels in cerebellar white matter of AD sub-
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jects. Moreover, there was a clear association 
in the pattern of labeling of the GFAPccp anti-
body with beta-amyloid deposition suggesting 
a potential interaction between astrocytes and 
deposited beta-amyloid. The presence of path-
ological white matter changes within the cere-
bellum may contribute to the gait and balance 
abnormalities associated with AD. 
Materials and methods
Antibody dilutions
The rabbit GFAPccp (in house, 1:100). The anti 
beta-amyloid mAb 1560 clone 6E10 (1:400), 
and PHF-1 (mouse monoclonal, 1:1000). The 
mAb TauC3 (caspase-cleaved tau) was utilized 
at 1:100. To visualize beta-amyloid staining, 
sections were pretreated for 5 minutes in 95% 
formic acid. To assess apoptosis, the Apoptag 
peroxidase kit was employed according the 
manufacturer’s instructions (Millipore). 
Immunohistochemistry 
Autopsy cerebellum brain tissue from five neu-
ropathologically confirmed AD cases and five 
neuropathologically normal cases were stud-
ied. Human brain tissue sections used in this 
study was provided by the Institute for Memory 
Impairments and Neurological Disorders at the 
University of California, Irvine. Free-floating 50 
μm-thick sections were used for immunohisto-
chemical studies as previously described [20].
For single labeling, all sections were washed 
with 0.1 M Tris-buffered saline (TBS), pH 7.4, 
and then pretreated with 3% hydrogen peroxide 
in 10% methanol to block endogenous peroxi-
dase activity. Sections were subsequently 
washed in TBS with 0.1% Triton X-100 (TBS-A) 
and then blocked for thirty minutes in TBS-A 
with 3% bovine serum albumin (TBS-B). 
Sections were further incubated overnight at 
room temperature in various primary antibod-
ies as listed above. Following two washes with 
TBS-A and a wash in TBS-B, sections were incu-
bated in anti-rabbit or mouse biotinylated anti-
IgG (1 hour) and then in avidin biotin complex (1 
hour) (ABC, Elite Immunoperoxidase, Vector 
Laboratories, Burlingame, CA, USA). Antibodies 
were visualized using Brown DAB substrate 
(Vector Laboratories). For bright-field immuno-
histochemical double labeling, primary anti-
body labeling was detected using the brown 
DAB substrate (Vector Labs), while the second 
label was visualized using the Blue SG sub-
strate (Vector Labs).
Immunofluorescence microscopy
Immunofluorescence studies were performed 
by incubating sections with primary antibody 
overnight at a room temperature, followed by 
secondary anti-rabbit or mouse biotinylated 
anti-IgG (1 hour) and then in ABC (1 hour). 
Visualization was accomplished by using a tyra-
mide signal amplification kit (Molecular Probes, 
Eugene, OR) consisting of Alexa Fluor 
488-labeled tyramide (green, Ex/Em = 
495/519). For immunofluorescence co-local-
ization studies, antigen visualization was 
accomplished using an Alexa fluor 488-labeled 
tyramide (green, Ex/Em = 495/519) for one 
label and streptavidin Alexa fluor 555 (red, Ex/
Em = 555/565) for the second label, both from 
Invitrogen (Carlsbad, CA). 
Results
Caspase-cleaved GFAP in cerebellar white mat-
ter of the AD brain
As an initial approach, we screened cerebellum 
tissue sections from AD subjects or age-
matched controls utilizing our in house GFAPccp 
antibody that detects caspase-cleaved GFAP 
within degenerating astrocytes [17]. 
Immunohistochemical analysis revealed wide-
spread labeling of the GFAPccp antibody princi-
pally within white matter of AD cerebellum tis-
sue sections (Figure 1A). In contrast, we 
observed very little staining of the GFAPccp 
antibody in age-matched control sections in 
either white or gray matter of the cerebellum 
(Figure 1B). Closer examination of the GFAPccp 
labeling in AD sections indicated strong stain-
ing of damaged astrocytes that were in close 
proximity to blood vessels. This type of staining 
was very similar to previous results that we 
found in hippocampal regions of the AD brain 
[17]. 
The GFAPccp antibody colocalizes with other 
markers of apoptosis
To confirm that labeling in cerebellar white mat-
ter of the GFAPccp antibody was occurring in 
astrocytes undergoing apoptosis, double-label 
experiments were performed using two addi-
tional markers for apoptosis including TUNEL 
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and caspase-cleaved tau. Using TUNEL label-
ing, we confirmed both by bright field and immu-
nofluorescence the colocalization with GFAPccp 
within astrocytes in cerebellar white matter of 
the AD brain (Figure 2A and 2B). Additional 
experiments were carried out using an antibody 
that selectively detects caspase-cleaved tau. 
This antibody, termed TauC3 recognizes the 
C-terminal cleavage fragment of tau following 
cleavage at D421 and has been used as a 
marker for the activation of apoptosis in the AD 
brain [21]. Double-label immunofluorescence 
experiments utilizing GFAPccp together with 
the TauC3 antibody indicated strong colocaliza-
tion between the two markers (Figure 2C). 
Double labeling appeared to be confined to a 
large extent within damaged astrocytes along 
blood vessels in cerebellar white matter (Figure 
2C).
Association between beta-amyloid deposition 
and GFAPccp in cerebellar white matter of the 
AD brain
Experiments were performed to determine any 
possible relationship between the presence of 
caspase-cleaved GFAP with pathological fea-
tures of AD including beta-amyloid deposition 
and neuritic pathology. Staining of cerebellum 
sections with anti beta-amyloid mAb 1560 
clone 6E10 revealed diffuse, punctate beta-
amyloid deposition predominantly within white 
but not gray matter of the AD brain (Figure 3A 
and 3B). The diffuse pattern of labeling was in 
contrast to staining of beta-amyloid in AD fron-
tal cortex sections that led to the characteristic 
labeling of senile plaques containing a well-
defined core (Figure 3C). To identify a possible 
association between beta-amyloid deposition 
Figure 1. Caspase-cleaved GFAP in cerebellar white matter of the AD brain. A: Representative labeling in the cerebel-
lum of an AD case at low magnification utilizing the GFAPccp antibody indicated widespread labeling primarily in 
white but not gray matter. B: Representative labeling in a control case with the GFAPccp antibody revealed a relative 
absence of labeling in both white and gray areas of the cerebellum. C and D: High magnification of staining with the 
GFAPccp antibody in representative AD cases indicating labeling of degenerating astrocytes along blood vessels in 
the white matter of the cerebellum (arrows, C and D). Scale bars are: A, 100 µm; B, 300µm; C and D, 10 µm.
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and GFAPccp, double-labeling experiments 
were performed. In this case, the two markers 
often appeared localized within the same areas 
of white matter in the cerebellum (Figure 3D). 
In this regard, we often found damaged astro-
cytes labeled with GFAPccp that were in close 
proximity to diffuse plaques (arrowhead, Figure 
3D). In addition, GFAPccp-labeled astrocytes 
appeared to exhibit punctate beta-amyloid 
labeling upon their surface (arrows, Figure 3D). 
In contrast to the diffuse beta-amyloid deposi-
tion, we could find no evidence of any neuritic 
changes as indicated by the complete absence 
of PHF-1 labeling in the cerebellum of AD sub-
jects (Figure 3E). As a positive control, we per-
formed side-by-side staining of AD frontal cor-
tex sections with PHF-1, leading to the extensive 
staining of NFTs and neuropil threads as 
expected (Figure 3F).
Discussion
Although the major symptoms associated with 
AD are cognitive in nature, emerging data sug-
gests that motor dysfunction is an important 
component to the disease process. Thus, 
recent studies have documented gait and bal-
ance impairments as well as an increase risk 
Figure 2. Colocalization of the GFAPccp antibody with markers of apoptosis in the cerebellum of the AD brain. A: Rep-
resentative bright field microscopy image from the cerebellum of AD brain sections utilizing the GFAPccp antibody 
(blue) together with TUNEL labeling (brown) revealed labeling of apoptotic nuclei within degenerating astrocytes 
(arrows, A). The arrowhead in Panel A represents TUNEL labeling in the absence of GFAPccp staining. B: Confirma-
tion of colocalization in Panel A was confirmed following double-label immunofluorescence imaging, with GFAPccp 
fluorescence (red), TUNEL fluorescence (green), and where the two markers colocalized (yellow). C: Double-label im-
munofluorescence merged image utilizing an antibody to caspase-cleaved tau (red) and GFAPccp (green). The data 
indicated colocalization between the two markers along a blood vessel in white matter of the cerebellum (yellow). 
All scale bars represent 10µm.
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for falls [12-16]. Because of the predominant 
role that the cerebellum plays in providing for 
precise timing for coordinated movement, a 
likely hypothesis for explaining motor dysfunc-
tion in AD is some underlying dysfunction in this 
brain structure. However, the cerebellum has 
the distinction of being spared from the classic 
pathology of AD, namely plaques and tangles 
and because of this is often used as control 
region for comparison purposes (for example 
see, [4, 5]). Several studies have documented 
the presence of beta-amyloid deposition in the 
cerebellum [9-11] but there is very little evi-
dence for any neuropathological changes 
including the presence of NFTs [7, 8]. The pur-
pose of the present study was to examine the 
Figure 3. Association of GFAPccp with beta-amyloid deposition within white matter of the cerebellum in the AD brain. 
A-B: Representative labeling with anti-Ab antibody, clone 6E10 at low (A) and high (B) magnification in representa-
tive cerebellum AD brain sections indicated diffuse staining predominately within white matter (left half of Panel 
A). Scale bars represent 20 µm in Panel A and 10 µm in Panel B. C: Illustrates comparison staining with the same 
antibody utilizing frontal cortex AD sections revealing labeling of amyloid plaques with a central core. D: Double-
immunofluorescence labeling in the cerebellum of a representative AD case utilizing anti-Ab antibody, clone 6E10 
(red) and GFAPccp antibody (green) indicated a close association between the two markers within white matter. 
Arrows in Panel D represent putative degenerated astrocytes while arrowhead in same panel designates a diffuse 
plaque. Scale bars in Panels C and D are equivalent to 10 µm. E and F: Representative staining of the AD brain using 
the tangle marker, PHF-1 in cerebellum (E) and frontal cortex (F) indicated a complete lack of neuritic pathology in 
the cerebellum as compared to frontal cortex. Scale bars in Panels E and F represent 20µm.
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cerebellum in AD for other pathological fea-
tures in addition to beta-amyloid and NFTs. 
Numerous studies have suggested the activa-
tion of apoptotic pathways in the AD brain. In 
this regard, the activation of caspases and 
cleavage of critical proteins including beta-
amyloid, tau, fodrin, and GFAP may promote the 
underlying pathology associated with AD (for 
review see [22]). To date, whether the activa-
tion of apoptotic pathways occurs in the cere-
bellum has not been investigated. Therefore, 
we examined cerebellar AD brain sections 
employing a custom-made, in house antibody 
(GFAPccp) that specifically detects caspase-
cleaved GFAP within degenerating astrocytes 
[17-19]. Application of GFAPccp revealed wide-
spread labeling in white matter of cerebellar AD 
sections, while little staining was noted in age-
matched control sections. Specifically, GFAPccp 
labeled damaged astrocytes in white matter 
that were often localized near blood vessels. 
The morphological appearance of GFAPccp-
labeled astrocytes suggested that these cells 
were severely damaged and exhibited charac-
teristics of apoptosis. These results mirrored 
our previous findings with the GFAPccp anti-
body in AD hippocampal sections [17]. One 
important role of astrocytes is in the formation 
of the blood-brain barrier and in this role, astro-
cytes confer a protective role against hypoxia 
and aglycemia by extending end feet that 
encapsulate brain capillaries [23]. Our current 
results suggest that activation of apoptotic 
pathways and cleavage of cytoskeletal pro-
teins, such as GFAP and tau, may be one of 
many factors that contribute to the compro-
mised blood-brain barrier observed in AD 
[24-27].
Another finding of the present study was the 
apparent association between beta-amyloid 
deposition and caspase-cleaved GFAP in cere-
bellar white matter. Diffuse beta-amyloid stain-
ing was observed in white matter but was rarely 
found in gray matter of AD cerebellum sections. 
Moreover, double-label immunofluorescence 
experiments revealed punctate beta-amyloid 
staining on GFAPccp-labeled astrocytes 
(arrows, Figure 3D). We observed a similar rela-
tionship in AD hippocampal brain sections [17] 
and taken together the results suggest that 
astrocytes are activated and recruited to sites 
of beta-amyloid deposition. Several studies 
have now documented the important role that 
astrocytes may play in clearing beta-amyloid 
via the ability to internalize deposited beta-
amyloid peptides [28, 29]. In the process of 
clearing beta-amyloid, astrocytes themselves 
may be subjected to beta-amyloid-induced tox-
icity leading to the activation of apoptosis and 
eventual degeneration. Indeed, in a previous 
report we documented the ability of beta-amy-
loid to induce apoptosis and caspase-cleavage 
of GFAP in cultured astrocytes [17]. White mat-
ter labeling of degenerating astrocytes were 
independent of any neuropathological changes 
as evidenced by the complete lack of PHF-1 
labeling in all regions of AD cerebellar tissue 
sections (Figure 3E). 
In conclusion, results from the present study 
support the caspase cleavage of cytoskeletal 
proteins including tau and GFAP within astro-
cytes in cerebellar white matter of the AD brain. 
The cleavage of critical cytoskeletal proteins 
may lead to the breakdown of the framework of 
the astrocyte and contribute to astrocytic 
degeneration along blood vessels. It is suggest-
ed that these events may be initiated in astro-
cytes following their interaction with deposited 
beta-amyloid in white matter of the cerebellum. 
Although the cerebellum has historically been 
defined as a brain structure largely spared from 
AD pathology, recent clinical evidence indicat-
ing an increase risk for falls and impairment of 
gait and balance suggest otherwise. Our results 
provide a potential molecular mechanism 
involving astrocyte degeneration and disrup-
tion of the blood brain barrier in cerebellar 
white matter as a putative contributing factor 
to mobility impairments associated with AD.
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